Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage

Novo Nordisk and Eli Lilly bring their longtime rivalry to GLP-1 pills and prepare to make their pitch to seniors with Medicare.

lunedì 8 giugno 2026 New tab

1,217 words~6 min read

In this article

Novo Nordisk

and Eli Lilly

took their GLP-1 pill battle to the preeminent obesity meeting this weekend as they prepare for the next sea change in how patients receive their drugs.

Novo Nordisk on Sunday announced that prescriptions of the Wegovy pill have topped 3 million since it entered the U.S. market about five months ago. The Danish drugmaker's CEO Mike Doustdar celebrated the milestone, saying in an interview with CNBC that Novo was able to accelerate prescriptions even as Lilly introduced its own GLP-1 pill in April.

Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage

Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage

Other newsrooms on this story

Related reading

Eli Lilly, Novo Nordisk prepare to face off in the next obesity drug…

Other newsrooms on this story

Related reading

Eli Lilly, Novo Nordisk prepare to face off in the next obesity drug…

FDA approves first GLP-1 pill for obesity from Wegovy maker Novo Nordisk

Novo Nordisk’s Wegovy head start on pills forces investors to rethink Eli…

Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial…

Eli Lilly's obesity pill remains a viable rival to Novo's oral Wegovy despite…

2026 is the year of obesity pills. Here's how they could reshape the GLP-1…